PAI’s smart business move to skyrocket US injectable drug creation

Introduction

PAI Pharma is known for developing, processing and circulating the generic oral liquids, packed in bottles and ready to dose (RTD) in the US region. The company holds a wide range of generic oral liquid drugs that long served the giants like hospitals and pharmacies, considering the long term care for the disturbed patient group.

Whereas, US-based Nivagen Pharmaceuticals, Inc.'s key aim is to develop, manufacture and commercialize over the counter (OTC) products and popular prescription and generic drugs to boost the North American market’s profit rate. Since 2009, Nivagen has been delivering quality medicines at affordable prices via elevating processing and manufacturing collaborations for its own sterile manufacturing facility in different areas and in the R&D center as well.

Announcement

PAI Pharma buy-outs California based Nivagen Pharmaceutical and its comprehensive, ready-to-use (RTU) sterile injectables to further accelerate the injectable drug production. This brilliant business move represents PAI’s smart strategies evolution and dedication towards extending domestic pharmaceutical manufacturing. Alongside, it also leverages the growth factor in hospital-centric therapies and bolster supply chain. Basically, the strategy is to reach all those areas where there are drug shortages that disturb the US healthcare system.

Ideal deal

Nivagen is popular for its IV bags, prefilled syringes, cartridges and vials production and its promising pipeline of around 20 RTU injectable products. These products best align with the PAI’s previous sterile portfolio. Under this sterile portfolio, 10 are in the development queue, and four are commercialised products.

CEO of PAI Pharma, Kurt Orlofski, said, “PAI is a champion in RTU oral liquid medicines; adhering to this, the similar reliability, patient concern, and quality design develops naturally into RTU injectables.”

Partner at Olympus Partners, Griffin Barstis, “Olympus takes an honor to be able to continue the contribution to PAI as it extends its promising portfolio into sterile injectables. We feel this duo of Nivagen’s injectable platform and PAI’s strength and experience in RTU oral liquids generate a exceptional business strategy. This strategy is capable enough to deliver healthcare providers and hospitals quality and crucial drugs.”

This commendable strategy is linked to the main roots that hold purpose, such as alleviating dependency on foreign supply chains, promising undisruptive access, and centralising pharmaceutical production to fundamental drugs. This will be a relief for the US market and patients who have faced RTU injectables shortages for a long time and felt the need for extensive domestic potent impression across the US healthcare sector.